Background/Aims: The thaliana phytoalexin Camalexin has been proposed for the treatment of malignancy. Camalexin counteracts tumor growth in part by stimulation of suicidal death or apoptosis of tumor cells. Similar to apoptosis of nucleated cells, erythrocytes may enter suicidal death or eryptosis, which is characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Cellular mechanisms contributing to the complex machinery executing eryptosis include increase of cytosolic Ca 2+ activity ([Ca 2+ ] i ), oxidative stress, ceramide, protein kinase C and caspases. The present study explored, whether Camalexin induces eryptosis and, if so, to shed light on mechanisms involved. Methods: Phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, [Ca 2+ ] i from Fluo-3 fluorescence, ROS formation from DCFDA dependent fluorescence, and ceramide abundance utilizing specific antibodies. Results: A 48 hours exposure of human erythrocytes to Camalexin significantly increased the percentage of annexin-V-binding cells (≥ 10 µg/ml), significantly decreased forward scatter (≥ 5 µg/ml) and significantly increased Fluo-3-fluorescence (≥ 10 µg/ml), but did not significantly modify DCFDA fluorescence or ceramide abundance. The effect of Camalexin on annexin-V-binding was significantly blunted by removal of extracellular Ca 2+ , by kinase inhibitors staurosporine (1 µM) and chelerythrine (10 µM), as well as by caspase inhibitors zVAD (10 µM) and zIETDfmk (50 µM). Conclusions: Camalexin triggers cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane, an effect at least in part depending on Ca 2+ entry, as well as staurosporine and chelerythrine sensitive kinase(s) as well as zVAD and zIETD-fmk sensitive caspase(s).
Introduction
The thaliana phytoalexin and indole alkaloid camalexin (3-thiazol-2'-yl-indole) [1] [2] [3] [4] participates in the defense of plants against pathogens [2, [5] [6] [7] [8] . Moreover, the substance is effective against cancer cells [2, 9] . Camalexin counteracts malignancy at least in part by triggering of cancer cell apoptosis [10] [11] [12] [13] .
In analogy to apoptosis of nucleated cells, erythrocytes may enter eryptosis, the suicidal death of erythrocytes [14] . Hallmarks of eryptosis are cell shrinkage [15] and cell membrane scrambling with phosphatidylserine translocation to the cell surface [14] , events in common with apoptosis of nucleated cells. Erythrocytes lack, however nuclei and mitochondria, key organelles of apoptosis. Nevertheless apoptosis and eryptosis have a wide variety of triggers and signalling pathways in common [14] . Signaling involved in the triggering of eryptosis include increase of cytosolic Ca 2+ activity ([Ca 2+ ] i ) [14] , ceramide [16] , and oxidative stress [14] . Some stimulators of eryptosis are effective by activation of caspases [14, 17, 18] . Triggering of eryptosis may further involve stimulation of kinases [14] . Eryptosis is triggered by multiple xenobiotics [14, . Moreover, enhanced eryptosis is observed in several clinical conditions including dehydration [14] , hyperphosphatemia [14] , chronic kidney disease (CKD) [66, 67] , hemolytic-uremic syndrome [14] , diabetes [68] , hepatic failure [69] , malignancy [14] , sepsis [70] , sickle-cell disease [14] , beta-thalassemia [14] , Hb-C and G6PD-deficiency [14] , as well as Wilson's disease [71] .
The present study explored, whether Camalexin modifies eryptosis. To this end, human erythrocytes from healthy volunteers were exposed to Camalexin and phosphatidylserine surface abundance, cell volume, [Ca 2+ ] i , ROS formation, and ceramide abundance determined by flow cytometry.
Materials and Methods

Erythrocytes, solutions and chemicals
Fresh Li-Heparin-anticoagulated blood samples were kindly provided by the blood bank of the University of Tübingen. The study is approved by the ethics committee of the University of Tübingen (184/2003 V). The blood was centrifuged at 120 g for 20 min at 21 °C and the platelets and leukocytescontaining supernatant was disposed. Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO 4 , 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES; pH 7.4), 5 glucose, 1 CaCl 2 , at 37°C for 48 hours. Where indicated, erythrocytes were exposed for 48 hours to 5, 10, 15 and 20 µg/ml Camalexin (MedChem Express, Princeton, USA). Given the molecular weight of Camalexin (200 g/mol), 5 µg/ml corresponds to 25 µM. In order to estimate the impact of Ca 2+ entry, erythrocytes were exposed to Camalexin in the absence of extracellular Ca 2+ and presence of Ca 2+ chelator EGTA (1 mM, Merck Millipore, Darmstadt, Germany). To test for an involvement of kinases, erythrocytes were exposed for 48 hours to a combination of Camalexin and protein kinase C inhibitor staurosporine (Sigma Aldrich, Hamburg, Germany), or p38 kinase inhibitor SB 203580 (Tocris bioscience, Bristol, UK), or casein kinase inhibitor D4476 (Sigma Aldrich, Hamburg, Germany). In order to test for a role of caspases, erythrocytes were exposed for 48 hours to a combination of Camalexin and pan-caspase inhibitor zVAD (Tocris bioscience, Bristol, UK), 
Annexin-V-binding and forward scatter
Reactive oxidant species (ROS)
Oxidative stress was determined utilizing 2', 7'-dichlorodihydrofluorescein diacetate (DCFDA). After incubation, a 150 µl suspension of erythrocytes was washed in Ringer solution and stained with DCFDA (Sigma, Schnelldorf, Germany) in Ringer solution containing DCFDA at a final concentration of 10 µM. Erythrocytes were incubated at 37°C for 30 min in the dark and washed two times in Ringer solution. The DCFDA-loaded erythrocytes were resuspended in 200 µl Ringer solution and ROS-dependent fluorescence intensity was measured at an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur (BD).
Ceramide abundance
For the determination of ceramide, a monoclonal antibody-based assay was used. To this end, cells were stained for 1 hour at 37°C with 1 µg/ml anti-ceramide antibody (clone MID 15B4, Alexis, Grünberg, Germany) in PBS containing 0.1% bovine serum albumin (BSA) at a dilution of 1:10. The samples were washed twice with PBS-BSA. The cells were stained for 30 minutes with polyclonal fluorescein isothiocyanate (FITC) conjugated goat anti-mouse IgG and IgM specific antibody (Pharmingen, Hamburg, Germany) diluted 1:50 in PBS-BSA. Unbound secondary antibody was removed by repeated washing with PBS-BSA. The samples were analyzed by flow cytometric analysis with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. As a control, secondary antibody alone was used.
Hemolysis
Following incubation, the erythrocyte suspension was centrifuged for 3 min at 1600 rpm, 4°C, and the supernatant harvested. As a measure of hemolysis, the hemoglobin (Hb) concentration in the supernatant was determined photometrically at 405 nm. The absorption of the supernatant of erythrocytes lysed in distilled water was defined as 100% hemolysis.
Statistics
Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis was made using ANOVA with Tukey's test as post-test and t test as appropriate. n denotes the number of different erythrocyte specimens studied. Since different erythrocyte specimens used in distinct experiments are differently susceptible to triggers of eryptosis, the same erythrocyte specimens have been used for control and experimental conditions.
Results
The present study explored whether Camalexin stimulates eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and phospholipid scrambling of the cell membrane with phosphatidylserine translocation to the cell surface.
Erythrocyte volume was estimated from forward scatter which was determined utilizing flow cytometry. Prior to measurements, the erythrocytes were incubated for 48 hours in Ringer solution without or with Camalexin (5, 10, 15 and 20 µg/ml). As illustrated in Fig. 1 , Camalexin decreased erythrocyte forward scatter, an effect reaching statistical significance at 5 µg/ml Camalexin concentration.
Phosphatidylserine exposing erythrocytes were identified utilizing annexin-V-binding, as determined by flow cytometry. Prior to measurements, the erythrocytes were again phosphatidylserine exposing erythrocytes, an effect reaching statistical significance at 10 µg/ml Camalexin.
In order to test whether Camalexin triggers hemolysis, hemoglobin was determined in the supernatant. As a result, the percentage of hemolytic cells was similar following exposure Eryptosis is further stimulated by oxidative stress. Reactive oxygen species (ROS) was thus quantified utilizing 2′,7′-dichlorodihydrofluorescein diacetate (DCFDA). As a result, the DCFDA fluorescence was similar following exposure to 20 µg/ml Camalexin (16.3 ± 2.0, a.u., n = 10) and in the absence of Camalexin (15.3 ± 1.6, a.u., n = 10). Thus, Camalexin did not appreciably induce oxidative stress (data not shown).
A further stimulator of eryptosis is ceramide. Ceramide abundance at the erythrocyte surface was thus quantified utilizing specific antibodies. As a result, the ceramide abundance was similar following exposure to 20 µg/ml Camalexin (7.5 ± 0.5 a.u., n = 10) and in the absence of Camalexin (7.1 ± 0.8 a.u., n = 10). Thus, Camalexin did not appreciably induce ceramide abundance (data not shown). To explore, whether the effects of Camalexin involved kinase activity, the influence of Camalexin on annexin-V-binding and forward scatter was tested in the presence of protein kinase C inhibitors staurosporine (1 µM) and chelerythrine (10 µM), p38 kinase inhibitor SB 203580 (2 µM) or casein kinase inhibitor D4476 (10 µM). As illustrated in Fig. 5 , the effect of Camalexin (20 µg/ml) on phosphatidylserine exposure was significantly blunted by staurosporine and chelerythrine. The percentage of annexin-V-binding erythrocytes following exposure to 20 µg/ml Camalexin was, however, similar in the absence of inhibitors (15.7 ± 3.0 a.u., n = 10) and in the presence of either SB203580 (11.3 ± 6.8 a.u., n = 10, data not shown) or D4476 (12.4 ± 4.5 a.u., n = 10, data not shown). Thus, the full effect of Camalexin required staurosporine and chelerythrine sensitive but not SB203580 sensitive or D4476 sensitive kinases.
In order to test for the involvement of caspases, the influence of Camalexin on annexin-V-binding and forward scatter was tested in the presence of pancaspase inhibitor zVAD (10 µM), of caspase-8 inhibitor zIETD-fmk (50 µM), and of caspase-3 inhibitor zDEVD (50 µM). As illustrated in Fig. 6 , the effect of Camalexin (20 µg/ml) on phosphatidylserine exposure was significantly blunted by zVAD and zIETD-fmk. The percentage of annexin-V-binding erythrocytes following exposure to 20 µg/ml Camalexin was, however, similar in the absence of inhibitors (16.9 ± 2.9 a.u., n = 8) and in the presence of zDEVD-fmk (19.1 ± 1.9 a.u., n = 8, data not shown).
Discussion
The present observations reveal a stimulating effect of Camalexin on suicidal erythrocyte death or eryptosis. Exposure of human erythrocytes to Camalexin is followed by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. In contrast, at the concentrations tested, Camalexin did not significantly modify hemolysis.
The effect of Camalexin on eryptosis was paralleled by an increase of cytosolic Ca The effect of Camalexin on phosphatidylserine translocation further apparently involves staurosporine and chelerythrine sensitive kinases such as protein kinase C. Accordingly, the effect of Camalexin on cell membrane scrambling was significantly blunted in the presence of protein kinase C inhibitor staurosporine, but not in the presence of p38 kinase inhibitor SB203580 and casein kinase inhibitor D4476. Camalexin-induced cell membrane scrambling was further significantly blunted in the presence of pan-caspase inhibitor zVAD and caspase 8 inhibitor zIETD-fmk, thus apparently involving activation of caspases. Increase of cytosolic Ca 2+ concentration, activity of staurosporine and chelerythrine sensitive kinases as well as activated caspases are well known triggers of eryptosis [14] . Camalexin triggered cell membrane scrambling and cell shrinkage without enhancing the ceramide abundance. Moreover, Camalexin triggered eryptosis without inducing oxidative stress. Both, ceramide and oxidative stress are well known stimulators of eryptosis [14] Consequences of eryptosis include rapid clearance of defective erythrocytes from circulating blood [14] . Failure of erythrocyte injury to trigger eryptosis may lead to hemolysis with release of hemoglobin, which passes the renal glomerular filter, precipitates in the acidic lumen of renal tubules, occludes nephrons and thus may lead to renal failure [72] . The rapid clearance of phosphatidylserine exposing erythrocytes from circulating blood could result in anemia as soon as the loss of erythrocytes surpasses the formation of new erythrocytes by erythropoiesis [14] . Phosphatidylserine exposing erythrocytes may further impair microcirculation [16, [73] [74] [75] [76] [77] due to adherence of eryptotic erythrocytes to the vascular wall [78] , stimulation of blood clotting and triggering of thrombosis [73, 79, 80] , To the extent that the effective concentrations are reached in plasma of Camalexin treated patients, side effects of the drug could include anemia and impaired microcirculation with increased risk of thrombosis.
In conclusion, Camalexin triggers eryptosis with cell shrinkage and cell membrane scrambling, an effect in large part dependent on Ca 2+ entry, staurosporine sensitive kinases and zVAD-sensitive caspases.
